What Happened?
Victoria, BC-based Eupraxia-Pharmaceuticals Resigned Alexander Rothwell as Chief Financial Officer
Date of management change: May 03, 2021
Victoria, BC-based Eupraxia-Pharmaceuticals Resigned Alexander Rothwell as Chief Financial Officer
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
Alexander Rothwell is Chief Financial Officer at Eupraxia Pharmaceuticals. Previously, Alexander held various senior HR leadership roles in the industry.
Press Release
Other IT executives who recently changed jobs as well: Chaudhry Irfan, Eversen Denis, Cheong Angela, Stang April, Boswell Duane, Raucher Steven, Hadley Chris, Haugh Lisa, Johnson Jovina, VanVurst Maria, Tsukamoto Zetta
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.